Sana Biotechnology, Inc. (SANA) stock
SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.74−0.11 (-5.95%)
Close on Nov 19, 2026Market cap $520.89MP/E –Yield –
Sana Biotechnology total assets
Total assets on the balance sheet at the end of each period.
Sana Biotechnology's total assets was $431.52M at Jun 30, 2026. For fiscal 2025 it was $416.89M, down 16.8% from the year before. The highest annual figure on record is $1.13B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $416.89M | -16.8% |
| FY2024 | Dec 31, 2024 | $501.02M | -11.4% |
| FY2023 | Dec 31, 2023 | $565.30M | -31.3% |
| FY2022 | Dec 31, 2022 | $822.72M | -27.2% |
| FY2021 | Dec 31, 2021 | $1.13B | +54.7% |
| FY2020 | Dec 31, 2020 | $730.30M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $431.52M | +19.3% |
| Q1 FY2026 | Mar 31, 2026 | $373.59M | -16.1% |
| Q4 FY2025 | Dec 31, 2025 | $416.89M | -16.8% |
| Q3 FY2025 | Sep 30, 2025 | $435.43M | -22.2% |
| Q2 FY2025 | Jun 30, 2025 | $361.65M | -41.5% |
| Q1 FY2025 | Mar 31, 2025 | $445.47M | -34.6% |
| Q4 FY2024 | Dec 31, 2024 | $501.02M | -11.4% |
| Q3 FY2024 | Sep 30, 2024 | $559.39M | -11.4% |
| Q2 FY2024 | Jun 30, 2024 | $618.67M | -12.5% |
| Q1 FY2024 | Mar 31, 2024 | $681.38M | -8.8% |
| Q4 FY2023 | Dec 31, 2023 | $565.30M | -31.3% |
| Q3 FY2023 | Sep 30, 2023 | $631.44M | -29.7% |
| Q2 FY2023 | Jun 30, 2023 | $707.15M | -27.2% |
| Q1 FY2023 | Mar 31, 2023 | $746.93M | -28.7% |
| Q4 FY2022 | Dec 31, 2022 | $822.72M | -27.2% |
| Q3 FY2022 | Sep 30, 2022 | $898.10M | -27.1% |
| Q2 FY2022 | Jun 30, 2022 | $971.09M | -22.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.05B | -19.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.13B | +54.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.23B | – |
| Q2 FY2021 | Jun 30, 2021 | $1.26B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.30B | – |
| Q4 FY2020 | Dec 31, 2020 | $730.30M | – |
See a number that looks wrong?